|
Advertisement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
J. Biol. Chem., Vol. 277, Issue 4, 2709-2715, January 25, 2002
From the
Received for publication, September 20, 2001, and in revised form, October 10, 2001
Hydrogen bonds (H-bonds) are crucial for the
stability of the peptide-major histocompatibility complex (MHC)
complex. In particular, the H-bonds formed between the peptide ligand
and the MHC class II binding site appear to have a great influence on
the half-life of the complex. Here we show that functional groups with
the capacity to disrupt hydrogen bonds (e.g. -OH) can
efficiently catalyze ligand exchange reactions on HLA-DR molecules. In
conjunction with simple carrier molecules (such as propyl or benzyl
residues), they trigger the release of low affinity ligands, which
permits the rapid binding of peptides with higher affinity. Similar to HLA-DM, these compounds are able to influence the MHC class II ligand
repertoire. In contrast to HLA-DM, however, these simple small
molecules are still active at neutral pH. Under physiological conditions, they increase the number of "peptide-receptive" MHC class II molecules and facilitate exogenous peptide loading of dendritic cells. The drastic acceleration of the ligand exchange on
these antigen presenting cells suggests that, in general, availability of H-bond donors in the extracellular milieu controls the rate of MHC
class II ligand exchange reactions on the cell surface. These
molecules may therefore be extremely useful for the loading of antigens
onto dendritic cells for therapeutic purposes.
Peptide ligands bind to the peptide-binding groove of
MHC1 class II molecules by an
array of intermolecular hydrogen bonds (H-bonds). These hydrogen bonds
are mostly formed between the backbone of the peptide and conserved
residues of the MHC class II molecule. Some of these H-bonds are
particularly crucial for the stability of the ligand complex (1). It
has been shown for a murine MHC class II molecule that the elimination
of H-bonds between the ligand and residues His-81 or Asp-82 of the
I-Ad Because H-bonds appear to be fundamental in maintaining the stability
of the MHC class II peptide complexes, we started to investigate small
molecules capable of disrupting H-bonds with the goal of achieving an
HLA-DM-like catalytic effect on the kinetics of peptide binding.
H-bonds require a hydrogen donor and an acceptor group, which provides
a free electron pair. Some of the functional groups that can fulfill
this function are hydroxyl or amino groups. They are present in a
variety of natural and synthetic molecules, such as lipids,
metabolites, amino acids, and pharmaceutical drugs. One example is
ethanol, where the well known physiological effects appear to result
from subtle conformational changes of neurotransmitter receptors caused
by the disruption of H-bonds (8, 9). To show that hydroxyl or other
H-bond-forming functional groups (in conjunction with appropriate small
carrier molecules) can in fact mimic the catalytic activity HLA-DM
would not only provide additional support for the postulated function
of H-bonds as a molecular basis of the mechanism (6, 7, 10), it would
also suggest that in general the availability of molecules with H-bond
forming capacity in the extracellular milieu controls the rate and
extent of ligand exchange on the cell surface.
Small molecular compounds with peptide complex destabilizing capacity
would also represent powerful tools to enhance the efficiency of
HLA-DM-independent ligand exchange reactions, which take place, for
example, on the cell surface of antigen presenting cells. A series of
studies has already been published that describes successful
immunotherapies based on the reinjection of antigen-loaded dendritic
cells (DC) (11-15). The major goal of these attempts is to deliver
high amounts of immunogenic peptide antigens derived from
tumor-specific or tumor-associated proteins. In addition to the benefit
of increased loading rates, these small molecular catalysts would also
allow the bypassing of proteolytic endosomal processing compartments,
which facilitates the presentation of epitopes sensitive to proteolytic
degradation when following the classical MHC class II presentation pathway.
Previous studies have already shown that, under certain conditions, the
stability of peptide-MHC complexes can be affected by detergents or
detergent-like compounds (16, 17). The mechanism, however, remained
obscure, and the chemical nature of these compounds did not allow any
experiments with living cells. In this study we tested the effect of
simple H-bond donor/acceptor molecules, such as ethanol,
n-propanol, phenol, and aniline on the ligand exchange of
MHC class II molecules. By utilizing both soluble HLA-DR molecules and
cellular in vitro systems, we evaluated the effect on the
molecular level as well as under physiological conditions in cell
assays (including T cell stimulation experiments). Because of potential
implications for the induction of autoimmune reactions, autoantigens,
such as the encephalitogenic MBP86-100 epitope (derived from the
myelin basic protein), together with allelic forms of MHC class II
molecules associated with the development of autoimmune diseases
(e.g. HLA-DR2) were included in this study.
Reagents and Peptide Ligands--
Most reagents were obtained
from Sigma (n-propanol, n-butanol, phenol,
n-propylamine, aniline); para-chlorophenol was
obtained from Fluka. The peptides IC106-120 (CLIP) (KMRMATPLLMQALPM)
(18), MBP86-100 (NPVVHFFKNIVTPRT) (19), HA306-318 (PKYVKQNTLKLAT) (20), and PLP139-151(C140S) (HSLGKWLGHPDKF) (21, 22) were synthesized
by using standard solid phase Fmoc
(N-(9-fluorenyl)methoxycarbonyl) chemistry. For biotinylated
peptides the biotin was attached to the N terminus of peptides, which
were extended by a short amino acid spacer sequence (SGSG). All
peptides were obtained from the Biopolymers Laboratory at Harvard
Medical School.
Production of Soluble MHC Class II Molecules--
Soluble MHC
class II molecules HLA-DR1 (DRA1*0101, DRB1*0101) (4) and HLA-DR2
(DRA1*0101, DRB1*1501) (23) and soluble HLA-DM molecules (4) were
produced in S2 insect cells stably transfected with vectors encoding
truncated MHC SDS-PAGE Separation of Peptide-MHC Complexes--
Complexes were
formed in a volume of 6 µl by incubating 0.5 µg/ml HLA-DR with 0.16 µg/ml peptide ligand in the presence of 5% ethanol or 0.07 µg/ml
soluble HLA-DM for 4 h at 37 °C at pH 5.0 (25 mM
sodium acetate/sodium phosphate, 37.5 mM NaCl). After incubation pH was raised to 7.3, and after an additional 20 min at
37 °C the samples were separated by SDS-PAGE. SDS-PAGE separation was done on a 4-15% Tris-glycine gradient gel (Bio-Rad) at 4 °C. Samples were loaded without prior boiling using a nonreducing sample
buffer. A protein standard of 25-150 kDa (Novagen) was used as a
marker. Protein bands were visualized by silver stain.
ELISA Experiments--
Preformed CLIP peptide-HLA-DR complexes
were generated by incubating 10 µl of HLA-DR (1 mg/ml) with 0.5 µl
of biotinylated CLIP peptide (1 mg/ml) for 18-24 h at 37 °C. For
peptide release experiments, the reaction was diluted 1:5 with
phosphate-buffered saline. 4 µl of the dilution were mixed with 4 µl of buffer (100 mM Na2HPO4, 100 mM sodium acetate, 150 mM NaCl; the pH was
adjusted to 5.0 or 7.3). Depending on the experiment, indicated amounts of excess peptide and/or catalyst (HLA-DM or small molecule) were added
to a total volume of 10 µl. The reaction mixture was incubated for
3 h at 37 °C. In some release experiments, high amounts of high
affinity peptides were added to prevent binding of already released
CLIP peptide. The release reaction was added to ELISA plates,
previously coated with an FACS Analysis of Empty MHC Class II Molecules on Dendritic
Cells--
Dendritic cells were isolated from the bone marrow of SJL/J
mice (Jackson) and established by ex vivo differentiation of
precursor cells as described (24). Briefly, cultures were maintained in DMEM plus 5% FCS supplemented every 2 days with 10 ng/ml
granulocyte/macrophage colony-stimulating factor. B cells, T cells, and
granulocytes were removed by using rat monoclonal antibodies
(PharMingen) B220/CD45R, CD90.2/Thy 1.2, and Ly6GGR-1/RB6-8C5, in
conjunction with magnetic beads coated with sheep anti-rat IgG (Dynal,
Great Neck, NY), first on initial isolation from bone marrow and again
immediately before staining. Cell surface expression of empty MHC class
II molecules was determined by flow cytometry as described (25, 26).
For peptide binding DC (5 × 105) were incubated at
37 °C in the absence or presence of peptide ligands in DMEM
supplemented with or without 2% of n-propanol, 10 µM iodoacetamide, 1 µM EDTA, 0.02%
NaN3, 1 µM deoxyglucose for 4 h. For
staining DC were incubated on ice with saturating amounts of primary
antibody for 30 min in phosphate-buffered saline (150 mM
NaCl, 10 mM sodium phosphate, 12 mM
NaN3, pH 7.2) containing 1 mg/ml bovine serum albumin, 10 µM iodoacetamide, 1 µM EDTA, 0.02%
NaN3, 1 µM deoxyglucose and then washed,
incubated with phycoerythrin-conjugated (Fab')2 secondary
antibody (Jackson Immunoresearch) that had been preabsorbed with normal
serum, washed again, and analyzed immediately by using a FACScalibur
flow cytometer (Becton Dickinson). The primary antibody used in
cytometry, KL-304 (anti-IAs,k,u,f Cell Surface Peptide Loading Assay--
MHC class II negative
mouse L cells L929 (American Type Culture Collection) and fibroblast
cells transfected with HLA-DR1 (L57.23; HLA-DRA1*0101, HLA-DRB1*0101;
provided by E. Rosloniec) or HLA-DR2 (L466; HLA-DRA1*0101,
HLA-DRB1*1501; provided by K. Wucherpfennig) were incubated with
titrated amounts of biotinylated peptide ligands in DMEM plus 5% FCS
supplemented with or without 2% n-propanol for 4 h at
37 °C. Cells were then washed and stained with
streptavidin-phycoerythrin and analyzed by flow cytometry using a
FACScalibur instrument (Becton Dickinson). In some experiments, splenocytes from HLA-DR1 tg B10.M mice (provided by D. Zaller) were
also used.
T Cell Assay--
HLA-DR-expressing fibroblast cells L57.23
(HLA-DR1) and L466 (HLA-DR2) were incubated for 4-6 h with titrated
amounts of peptide antigens in DMEM plus 5% FCS supplemented with or
without 2% n-propanol (5 × 104
cells/well). The cells were then washed twice and incubated for 24 h with 5 × 104 cells/well of the MBP86-100-specific
T cell hybridoma 08073 (provided by L. Fugger) or the
HA306-318-specific CH7C17 T cells, a T cell receptor-transfected
Jurkat cell line (provided by L. Stern with kind permission of L. R. Wedderburn) in DMEM plus 5% FCS. T cell response was determined by
analyzing the interleukin-2 release in a secondary assay with
CTLL cells (28).
Ethanol is one of the simplest small molecules with H-bond forming
capability (8). To test the influence on peptide loading, soluble
HLA-DR1 molecules were incubated with a high affinity peptide ligand
(HA306-318) in the presence of ethanol or soluble HLA-DM. After 4 h of incubation, complex formation was analyzed by SDS-PAGE (Fig.
1). As expected the presence of HLA-DM
significantly increased the amount of peptide complex (Fig. 1,
lane 4). The band representing the SDS-stable
HA306-318·HLA-DR1 complex was clearly evident in the
HLA-DM-containing sample, whereas the band was much fainter when no
catalyst was present (lane 2). However, the same effect was
also evident when ethanol instead of HLA-DM was used (lane
3). The intensity of the staining of the band was even higher than
in the HLA-DM sample, indicating that more peptide-MHC complex was
generated by ethanol.
Because ethanol displayed some HLA-DM-like catalytic activity in the
loading experiment, the effect of the small molecule and of HLA-DM was
further compared in ELISA experiments. In the experiment shown in Fig.
2, the capacity of the two
"catalysts" to exchange ligands was determined by the release of
CLIP peptide from HLA-DR2 in the presence of titrated amounts of free
peptides with different affinities to the HLA-DR2 molecule (MBP86-100, high affinity; IC106-120, medium affinity; HA306-318, low affinity). Because HLA-DM requires endosomal pH to exhibit optimal activity, the
first part of the experiment was carried out at pH 5.0 (Fig. 2A). As expected the influence of HLA-DM (middle
panel) was most evident in the presence of the high affinity
peptide MBP86-100. An almost complete release of the biotinylated CLIP
peptide was detected at a concentration of only 10 µg/ml MBP86-100,
whereas in the presence of the IC106-120 or HA306-318 peptide little
difference to the noncatalyzed control reaction (upper
panel) was observed. However, the same result was also
obtained with 5% ethanol (lower panel). Ethanol
catalyzed the exchange of CLIP by MBP86-100 but did not enhance the
exchange by IC106-120 or HA306-318. Thus, ethanol can mediate the
replacement of peptides according to their affinity. In contrast to
HLA-DR2, a release of CLIP from HLA-DR1 by ethanol was not seen, which
was due presumably to the higher affinity of the CLIP peptide to
HLA-DR1 (data not shown).
In the second part of this experiment, the effectiveness of HLA-DM and ethanol on the ligand release was tested under physiological conditions (Fig. 2B). It is known that HLA-DM molecules show little or no catalytic activity at pH 7.0 (4, 29-31). In accordance with these reports, almost no release of biotinylated CLIP peptide from HLA-DR2 molecules was observed at pH 7.3. Approximately 80% of the CLIP·HLA-DR2 complexes were still detectable after the incubation with HLA-DM and 10 µg/ml MBP86-100. Compared with HLA-DM the ligand exchange capacity of ethanol appeared to be only slightly reduced at pH 7.0. After incubation with ethanol and 10 µg/ml high affinity peptide, less than 12% of the HLA-DR2 molecules were still loaded with CLIP. The different exchange capacity of ethanol and HLA-DM at neutral pH is presumably because of the fact that the dipole moment of ethanol's hydroxyl group remains unchanged upon pH shifts from 5.0 to 7.0, whereas conformational transitions abrogate the catalytic activity of the HLA-DM molecule. The previous experiments indicated that ethanol in principle showed the
HLA-DM-like catalytic activity anticipated from an H-bond disrupting
small molecule. The amount needed, however, was still relatively high.
To identify more effective compounds, organic small molecules with
various functional groups were tested. Most effective were hydroxyl
groups in conjunction with hydrophobic carrier residues. For aliphatic
residues it was found that the catalytic activity increased with the
length of the chain (Fig. 3A).
Methanol (C1) had virtually no effect, ethanol
(C2) triggered a 50% release of the CLIP peptide at a
concentration of 600 mM, n-propanol at 140 mM, and n-butanol (C4) at a
concentration of 40 mM. The substitution of the hydroxyl
group by (positively charged) amino groups resulted in a complete loss
of catalytic activity. No release was therefore observed with
n-propylamine (Fig. 3B, upper
panel) or with n-octylamine (data not shown), one
of the detergent-like compounds previously reported to affect
full-length HLA-DR3 (16). Additionally, no release was seen with
ethanolamine, amino acids, and other charged molecules, indicating that
the presence of charged substituents abrogates the effect even when located distant to the H-bond donor group. Another group of molecules that failed to induce exchange reactions were the so-called "chemical chaperones" (32), which included compounds like Me2SO,
glycerol, and some other simple organic small molecules (data not
shown).
Aromatic compounds tended to be more effective ligand exchangers than aliphatic molecules. The activity of two of these compounds is shown in the lower panel of Fig. 3B. Phenol triggered a 50% release at a concentration of about 30 mM, and a similar effect was also seen with aniline (which carries an uncharged amino group because of mesomeric resonance). The requirement of a functional group with H-bond forming capacity is illustrated in Fig. 3C. Removal of the hydroxyl group or substitution of the hydrogen completely abrogated the effect, indicating that the small molecule has to function as an H-bond donor to affect the exchange rate of MHC class II molecules. Because small molecular H-bond donors retain effectiveness at neutral
pH, they were tested in cell assays under physiological conditions. In
contrast to the more potent phenol, n-propanol did not
affect the viability of cells. A series of experiments was therefore
conducted in which the influence of n-propanol on cell
surface ligand exchange was determined with MHC class II-expressing antigen presenting cells such as dendritic cells or transfected fibroblast cell lines. First, whether or not the exposure of
n-propanol results in the release of endogenous ligands was
examined. Because such a release should lead to an increase in the
amount of "empty" MHC molecules on the cell surface, the analysis
was carried out by FACS using the conformation-specific KL304 antibody
(27), which has been recently found to bind exclusively to empty MHC class II molecules (25, 26). FACS analysis of murine bone marrow-derived dendritic cells revealed that, after 4 h of
incubation with 2% n-propanol, the amount of empty MHC
class II molecules was indeed significantly increased (Fig.
4A). The median fluorescence of the KL304 staining was 81, whereas, in the absence of
n-propanol, a value of only 38 was measured.
To ensure that the incubation with n-propanol generated functional "peptide-receptive" MHC class II molecules that can be reloaded with high affinity peptides, the exposure of I-As-expressing dendritic cells was repeated in the presence of the PLP 139-151 peptide (Fig. 4B). KL304 staining revealed that, in the absence of n-propanol, the peptide caused only a slight reduction in the amount of empty MHC molecules. Only at the highest peptide concentration used (10 µg/ml) was a 26% decrease in the KL304 staining from a fluorescence median of 38 to 28 detected. With 2% n-propanol, however, the amount of detectable empty MHC class II decreased by almost 85% when the peptide was present during the incubation. The geometrical mean of the fluorescence of the KL304 staining was reduced from 81 (detected in the absence of the peptide) to 12 (detected with 10 µg/ml PLP139-151). Thus, n-propanol is able to generate functional empty MHC class II molecules on the surface of antigen presenting cells, which can efficiently be loaded with high affinity peptide ligands. The peptide loading was further analyzed with biotinylated peptides
(Fig. 5A). The staining with
phycoerythrin-labeled streptavidin allowed direct determination of the
amount of peptides bound on the cell surface by FACS analysis. For
these experiments fibroblast cells expressing HLA-DR1 or HLA-DR2 were
incubated with titrated amounts of biotin-HA306-318 and of
biotin-MBP86-100 peptide, respectively. In the presence of
n-propanol, the staining of HA306-318 on HLA-DR1-expressing fibroblast cells increased ~10-fold (upper
panel), whereas for MBP86-100 and HLA-DR2 the increase was
even 20-fold (lower panel). Here, a median
fluorescence of ~12 was determined at the highest peptide
concentration used (1 µg/ml), whereas in the absence of n-propanol only a value of 3 was measured. This value,
however, was already reached at a peptide concentration of about 50 ng/ml in the presence of 2% n-propanol. Notably, no surface
staining was detected on fibroblast cells not expressing MHC class II
molecules, which confirmed that MHC class II molecules were indeed
loaded with the peptides.
As shown in Fig. 5B, T cell assays were used to test whether the increase in loading efficiency also translated into improved T cell responses. HLA-DR-expressing fibroblast cells were loaded with peptide antigens in the absence or presence of n-propanol and used to challenge CH7CH17 T cells, a Jurkat cell line transfected with T cell receptor specific for HLA-DR1/HA306-318 (33) (upper panel), or the mouse T cell hybridoma 08073 specific for HLA-DR2/MBP86-100 (lower panel). In accordance with the previous peptide loading experiment, the HLA-DR1-restricted T cell response was triggered at ~10-fold lower concentrations when 2% n-propanol was present during the incubation of the antigen presenting cell with the HA306-318 peptide. HLA-DR2-restricted T cells needed less than 1/20 of the peptide concentration to be stimulated when the loading of MBP86-100 was carried out in the presence of n-propanol. The above cell experiments illustrate that the presence of
n-propanol significantly amplifies the T cell response by
lowering the threshold concentration of the free antigen. To identify
even more effective compounds, several modified small molecules were tested. Fig. 6A shows a
comparison between n-propanol and p-chlorophenol (pCP), an H-bond donor molecule where the ligand exchange activity could be improved by an additional substitution of the hydrophobic benzyl carrier residue. In this experiment the influence of the two
compounds was tested on the loading of HLA-DR2-expressing fibroblast
cells with biotinylated MBP86-100 peptide. To reach a fluorescence
median of 10 requires only 1 mM pCP. This is 200-fold less
than with n-propanol, where a concentration of 200 mM was needed to generate an equivalent signal. Specificity
and efficiency of pCP is particularly evident in the loading of
splenocytes from HLA-DR1 transgenic mice. The dot-plot chart in Fig.
6B demonstrates that efficient binding of biotinylated
HA306-318 peptide to the HLA-DR1 molecule of these cells is possible
only when 2 mM pCP is present during the incubation
(lower right panel). Without the
H-bond donor, almost no peptides were transferred onto the cell surface
HLA-DR molecules (lower left panel).
Notably, only the HLA-DR+ cell population was affected by
the treatment with pCP, which shows again the specificity of treatment
with H-bond donor molecules.
In this study we showed that small molecular compounds with H-bond forming capacity can mimic the action of HLA-DM. They accelerate the release of low affinity peptide ligands, generate peptide receptive forms, and mediate the exchange with other peptides. As in the case of HLA-DM, the ligand exchange takes place according to the affinity of the peptide to the MHC class II molecule. "Peptide editing" (34) is therefore an inherent feature of the MHC class II molecule, and catalysts, such as HLA-DM and small molecular H-bond donors, convert the MHC molecule into a state that enables it to perform ligand selection. Small molecular ligand exchange catalysts require an H-bond donor group
to be functional. Blockage or replacement of this group results in the
abrogation of the ligand release capacity. Crystal structure analysis
of HLA-DM (7) and of a mutated I-Ek molecule (35) indicated
that rapid ligand exchange is associated with alterations in the H-bond
network between peptide and MHC molecule. A prior study with mutated
I-Ad molecules (10) had already suggested that the
"selective" state is characterized by the loss of one or more of
the H-bonds connecting the ligand to the MHC binding site. It is
therefore not unlikely that this H-bond network is the target for both
HLA-DM and the small molecular compounds. Normal H-bonds can provide
between 1 and 2 kcal/mol, and, depending on the chemical environment, the contribution can even increase to more than 5 kcal/mol (36). Thermodynamically a reduction of binding energy by 2 kcal/mol translates into a decrease in the affinity by ~100-fold (3), a
decrease in affinity that is sufficient to trigger the release of
weakly bound ligands. Furthermore, other H-bonds formed within or
between the domains of the The exposure of cells to small molecular H-bond donors triggers
conformational changes of cell surface MHC that can be detected directly by antibodies. We showed previously that the structural transitions occurring in the region of residues 57-71 of the Although the ligand exchange by HLA-DM and by small molecular H-bond donors shares similarities, some differences are apparent. One striking difference is the pH dependence. HLA-DM was detected on the membrane of some antigen presenting cells (40, 41). Although it was reported to mediate some cell surface ligand exchange (41), its catalytic activity should be drastically reduced as the result of the neutral pH. In contrast to HLA-DM, the small molecules presented in this study are still very active under physiological conditions. They effectively catalyzed exchange reactions on soluble MHC molecules and also demonstrated that they can "edit" the composition of the ligand repertoire of antigen presenting cells. The classical MHC class II antigen processing and presentation pathway is designed to channel only peptide ligands on the surface, which primarily derive from exogenous proteins and are incorporated by defined endocytic or receptor-mediated uptake mechanisms. An alternative pathway seems to be the direct loading of surface MHC class II (42). This applies not only for fully processed peptide antigens but also for proteins or protein fragments. For several proteins, such as the encephalitogenic myelin basic protein (MBP) or hen egg lysozyme, it has been shown that they can bind directly to surface MHC class II molecules (43) and even extracellular processing mechanisms seem to exist (25). Hydroxyl groups or other functional groups capable of acting as H-bond donors are present in numerous natural and synthetic small molecules and macromolecules. The availability of these groups might therefore control rate and contribution of the HLA-independent presentation pathway. Our data revealed some allele-specific differences in the sensitivity of peptide-MHC complexes to small molecular H-bond donors. CLIP was removed only very inefficiently from HLA-DR1, whereas the CLIP complex of HLA-DR2 and of HLA-DR4 was found to be particularly easy to exchange (data not shown). Both molecules, HLA-DR2 and -DR4, are frequently connected with autoimmune diseases such as insulin-dependent diabetes mellitus, multiple sclerosis, Goodpasture's syndrome, rheumatoid arthritis, and pemphigus vulgaris (44). Autoantigens transferred onto MHC molecules of dendritic cells can "accidentally" provoke autoimmune reactions, which potentially develop into severe autoimmune diseases (45). Although the concentrations needed are still relatively high, more effective H-bond donor molecules that act as mediators of this process might exist representing environmental risk factors that have not been considered yet. The susceptibility of MHC class II molecules toward the destabilization by these compounds could represent an alternative link, which could explain the genetic correlation beyond the presentation of mimicry antigens. In conclusion, we provided evidence that small molecules capable
of disrupting H-bonds are able to trigger ligand exchange of MHC class
II molecules. All of the three alleles were sensitive to the exposure,
suggesting that in general they have a profound effect on the peptide
repertoire displayed at the cell surface. At this point the small
molecular H-bond donors tested so far are still structurally relatively
simple molecules. Nevertheless, they demonstrated surprisingly high,
and specific, catalytic activity. Subtle modifications have already
produced compounds that trigger ligand exchange at significantly
reduced concentrations, and it is very likely that more optimally
adapted compounds will be identified. Their use for external loading of
peptide antigens could be particularly beneficial in immunotherapies,
where specific epitopes must be loaded on antigen presenting cells to
induce a T cell-specific immune response.
We thank D. Zaller, D. Wiley, K. Wucherpfennig, L. Fugger, L. Stern, L. R. Wedderburn, and E. Rosloniec for cells and recombinant proteins, and H. Finlay, I. Liebner, and M. Hofstätter for excellent technical assistance.
* This work was supported by National Institutes of Health Grants 5R35-CA47554, N01-AI-45198, and R01-AI-48832.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
¶ The first two authors contributed equally to this work.
** To whom correspondence may be addressed: Max Delbrück Center for Molecular Medicine, Robert-Rössle-Str. 10, 13125 Berlin, Germany. Tel.: 49-30-9406-3664; Fax: 49-30-9406-2394; E-mail: roetzsch@mdc- berlin.de.
Published, JBC Papers in Press, October 15, 2001, DOI 10.1074/jbc.M109098200
The abbreviations used are: MHC, major histocompatibility complex; PE, phycoerythrin; pCP, p-chlorophenol; tg, transgenic; H-bond, hydrogen bond; DC, dendritic cell; FCS, fetal calf serum; DMEM, Dulbecco's modified Eagle's medium; MBP, myelin basic protein; ELISA, enzyme-linked immunosorbent assay; FACS, fluorescence-activated cell sorting..
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc. This article has been cited by other articles:
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Advertisement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||